ClearPoint Neuro, Inc. Announces First-in-Human Cases of the SmartFrame Array™ Neuro Navigation System and Software
18 mai 2021 16h05 HE
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling company providing navigation and delivery to the brain, today...
ClearPoint Neuro Reports Record Revenue in First Quarter 2021 Results, Announces FDA Clearance of the SmartFrame ‘Array’
11 mai 2021 16h05 HE
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
ClearPoint Neuro Announces Partnership With D&K Engineering for Development of Robotic System for the MRI Suite and Operating Room
10 mai 2021 17h21 HE
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
ClearPoint Neuro to Announce First Quarter 2021 Results May 11, 2021
29 avr. 2021 16h38 HE
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
ClearPoint Neuro, Inc. Congratulates Voyager Therapeutics on FDA Clearance of IND Application for Gene Therapy Candidate VY-HTT01 for Treatment of Huntington’s Disease
28 avr. 2021 16h05 HE
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
ClearPoint Neuro, Inc. Congratulates uniQure on Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
06 avr. 2021 16h05 HE
|
ClearPoint Neuro, Inc.
IRVINE, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain,...
ClearPoint Neuro, Inc. Announces Appointment of Ellisa Cholapranee as General Counsel
24 mars 2021 16h05 HE
|
ClearPoint Neuro, Inc.
IRVINE, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain,...
ClearPoint Neuro Reports Fourth Quarter and Full-Year 2020 Results
04 mars 2021 16h05 HE
|
ClearPoint Neuro, Inc.
Company Reports Record Revenues IRVINE, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing...
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2020 Results on March 4, 2021
19 févr. 2021 16h05 HE
|
ClearPoint Neuro, Inc.
IRVINE, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain,...
ClearPoint Neuro, Inc. Announces Multi-Product Joint Development & Option Agreement with Blackrock Microsystems
11 févr. 2021 16h05 HE
|
ClearPoint Neuro, Inc.
IRVINE, Calif. and SALT LAKE CITY, Utah, Feb. 11, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and...